Miscellaneous Products — Self‑Administered Drugs (SAD)
Customize your policy alerts
Sign up for all Providence Health Plan policy alerts
Know when Providence Health Plan releases new policies or updates existing guidance.
Monitor payer policy activity
Policy governing coverage, prior authorization, and medical necessity for miscellaneous self-administered drugs (SAD) for Providence Health Plan commercial and Medicaid members, including transition/monitoring provisions when administration in a provider office is requested.
No material clinical or coverage changes in this revision.
Coverage Criteria for Provider Administration and Transition
Criteria for healthcare provider administration
Provider administration may be considered medically necessary when ONE of the following is met:
From any cause; supports in‑office administration
Supports in‑office administration
Each subitem is an alternative enabling provider administration
Medical transition/monitoring
Transition/monitoring periods when initiating certain SADs:
Documented in Table 1; continuation of provider administration after transition requires meeting medical necessity criteria
Explicit example in policy
The policy specifies that subcutaneously administered drugs listed on the Usually Self-Administered list will be denied as a benefit exclusion. The Route of Administration Modifier rules require correct use of modifiers and explicitly state that subcutaneously administered drugs on that list are excluded from payment under the medical benefit. Claims for such items billed without appropriate coding may be denied per the policy's billing rules.
Table 1 identifies multiple SAD products that are designated “Pharmacy Benefit Only”. Items so marked are intended to begin and remain under the pharmacy benefit and are not payable under the medical benefit for administration; they are therefore not subject to the SAD medical-benefit exception process. Providers should use the Table 1 benefit designation when determining the prior authorization and billing pathway for a specific product.
The policy requires review whenever a medication is labeled for patient self-administration and a request is made for healthcare professional administration. While initial in-office administration is permitted for listed products during a defined monitoring/transition period, continuation of provider administration beyond that period is only allowed when the member meets the policy's medical necessity criteria. Relevant chart notes documenting the medical rationale for healthcare administration must be provided to support requests for continued provider-administered therapy.
HCPCS / J-code Listings and Coding Rules
| J3490 | Tymlos (Abaloparatide); Strensiq (Asfotase alfa); (also used for other listed brands) |
| J0129* | Orencia (Abatacept) - asterisk indicates multiple routes; JA/JB required |
| J0139 | Humira (Adalimumab) |
| Q5144 | Idacio (Adalimumab-aacf) |
| Q5141 | Yuflyma (Adalimumab-aaty) |
| J3590 | Multiple brands (e.g., Hyrimoz, Yusimry, Amjevita, Hadlima, etc.) |
| Q5143 | Cyltezo (Adalimumab-adbm) |
| Q5145 | Abrilada (Adalimumab-afzb) |
| Q5140 | Hulio (Adalimumab-fkjp) |
| Q5142 | Simlandi (Adalimumab-ryvk) |
| J3590 | Unclassified biologics / miscellaneous J-code (used for multiple listed products) |
| Q5140 | Hulio (adalimumab-bwwd) |
| Q5142 | Simlandi (adalimumab-ryvk) |
| J7999 | Tri-mix (Alprostadil, Papaverine, Phentolamine) |
| J0364 | Apokyn (Apomorphine) |
| J3490 | Unclassified drugs / J3490 entries for multiple listed products |
| J0517 | Fasenra (Benralizumab) |
| J0717 | Cimzia (Certolizumab pegol) |
| J0599 | Haegarda (C1 esterase inhibitor) |
| J0630 | Calcimar/Miacalcin (Calcitonin Salmon) |
Provider Requirements, Prior Authorization, and Billing
Prior Authorization Required
Prior Authorization Required: Medications listed on Table 1 that require prior authorization must meet the clinical criteria in this policy. Approval of a prior authorization is for self-administration at home unless the drug is designated in Table 1 as "Medical Transition Available," in which case a limited monitoring period (60 days, or 90 days for Xolair®) at the provider's office is allowed.
- PA approvals assume self-administration at home unless Medical Transition Available is indicated in Table 1
- Medical Transition Available = temporary office monitoring period (60 days; 90 days for Xolair®)
Use Table 1 to determine PA pathway
Use Table 1 (Self‑Administered Drug List) to determine the PA pathway and benefit designation for each product. Table 1 identifies the HCPCS/J‑codes, whether a product is Pharmacy Benefit Only or Medical, and whether Medical Transition is available.
- Follow the benefit designation in Table 1 to determine whether the drug is processed through the pharmacy benefit or as a medical benefit
- Table 1 lists the HCPCS/J‑codes and any Medical Transition availability
New / Off‑label Indication Review
New or off‑label indication review: Requests for indications approved by the FDA within the previous six (6) months will be reviewed under the New Drug/Indication Awaiting P&T Review process (Prior Authorization Request ORPTCOPS047). Requests for non‑FDA (off‑label) indications must be supported by listings in AHFS, Drugdex, or NCCN and will be evaluated based on prescriber rationale, available evidence, formulary alternatives, and whether the use is experimental/investigational.
- FDA approvals within prior 6 months → New Drug/Indication Awaiting P&T Review (ORPTCOPS047)
- Off‑label uses require listing in AHFS, Drugdex, or NCCN and will be reviewed for evidence and medical necessity
Coding and modifier denials
Coding and modifier requirements: Drugs listed in Table 1 that are marked with an asterisk (*) have one HCPCS Level II code but multiple routes of administration and must be billed with the appropriate route modifier. Claims for those drugs billed without the required modifier (JA or JB) will be denied.
- Asterisk (*) in Table 1 = single HCPCS code with multiple routes — JA or JB required
- Claims for asterisked drugs billed without JA or JB will be denied
Modifier‑related denial risk
Modifier‑related denial risk: Use JA for the intravenous infusion route and JB for the subcutaneous injection route. Items requiring a specific modifier may be denied or misprocessed if billed without the correct modifier. In addition, subcutaneously administered drugs listed as Usually Self‑Administered may be excluded from benefit when billed as a medical administration without appropriate justification.
- JA = Intravenous administration; JB = Subcutaneous administration
- Failure to append required modifier may result in denial or erroneous processing
- Subcutaneous drugs on the Usually Self‑Administered list may be denied as a benefit exclusion if billed as provider‑administered without justification
Key Definitions and Modifiers
Initiation Rules and Benefit Routing
Initiation and benefit routing
Initiation rules for drugs listed in Table 1
These products are intended for dispensation via the pharmacy benefit and are typically self‑administered at home
Step Therapy and New Indication Review
| Request type | Review pathway / requirements | Supporting references required | Coverage implication |
|---|---|---|---|
| FDA-approved indication (new within prior 6 months) | Will be reviewed using the New Drug and/or Indication Awaiting P&T Review process (Prior Authorization Request ORPTCOPS047) | N/A — plan review via P&T process | Coverage decision deferred pending P&T review and individualized medical necessity determination |
| Off‑label (non‑FDA approved) indication | Requires demonstration that the proposed indication is listed in AHFS, Drugdex, or NCCN and evaluation of prescriber medical rationale and available evidence | Citation of the specific listing in AHFS, Drugdex, or NCCN and prescriber rationale; supporting literature as available | Considered subject to evaluation; may be denied if considered experimental/investigational |
| Medicaid-specific requests | Coverage limited to conditions designated as covered line‑item numbers by the Oregon Health Services Commission (Prioritized List) | Reference to the designated covered line‑item number on the Prioritized List of Health Care Services | Coverage only if condition appears on the Prioritized List; otherwise not covered under Medicaid |
| General review considerations | Coverage decisions are individualized based on medical necessity and whether the treatment is experimental/investigational | Prescriber rationale, formulary alternatives, and available published evidence are considered | May be approved or denied following individualized determination |
Site of Care: Home vs Provider Office
Initial administration allowed in-office during transition period (60 days; 90 days for Xolair)
Initial administration may occur in the provider's office during the allowed medical transition/monitoring period: standard transitions listed as 'Medical Transition Available' are allowed 60 days in-office monitoring, and Xolair (omalizumab) initiation is allowed a 90-day in-office monitoring period.
Pharmacy Benefit Only items are for pharmacy dispensing and home self-administration
Products designated 'Pharmacy Benefit Only' in Table 1 are intended to be dispensed via the pharmacy benefit and are expected to be self-administered at home; these items start under the pharmacy benefit and are not subject to SAD medical benefit exception requirements.
Background
Self-administered drugs are medications identified as appropriate for safe and effective administration by a patient or caregiver without medical supervision. This policy balances patient convenience and cost containment with safety by: allowing selected products a limited in-office medical transition/monitoring period (see Table 1), requiring documentation when continued provider administration is requested, and defining clinical circumstances under which healthcare provider administration may be medically necessary.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.